ATLASRegeneron Pharmaceuticals (REGN) Q3 2026 earnings results
Regeneron Pharmaceuticals (REGN) reported EPS of $18.43 against an analyst estimate of $13.76: a beat of $4.67 (33.9%). The quarter ended Sep 30, 2026; the company reported on Friday, October 30, 2026, before the open.
Status: Confirmed · cross-checked Nov 2 · Source: EODHD (calendar and fundamentals, cross-checked)
Notify me when Regeneron Pharmaceuticals reports
Track REGN free Add Regeneron Pharmaceuticals to a free ATLAS watchlist.
REGN Q3 2026 results at a glance
| EPS reported | $18.43 |
|---|---|
| EPS estimate | $13.76 |
| Surprise | Beat · +$4.67 (+33.9%) |
| Quarter ended | Sep 30, 2026 |
| Reported | Oct 30, 2026, before the open |
| Status | Confirmed · cross-checked Nov 2 |
EPS is as supplied by EODHD, in US dollars per share; whether it is adjusted or GAAP follows that source. This is Regeneron Pharmaceuticals’s Q3 2026, a calendar-year company.
Regeneron Pharmaceuticals EPS surprise history: last 4 quarters
Regeneron Pharmaceuticals beat the EPS estimate in 4 of its last 4 reports, with an average surprise of +21.7%.
| Report date | EPS est. | EPS actual | Surprise | Result | Move* |
|---|---|---|---|---|---|
| Oct 30, 2026 | $13.76 | $18.43 | +33.9% | Beat | – |
| Jul 30, 2026 | $10.21 | $14.29 | +40.0% | Beat | +9.7% |
| Apr 29, 2026 | $8.90 | $9.47 | +6.4% | Beat | -3.4% |
| Jan 30, 2026 | $10.75 | $11.44 | +6.4% | Beat | +0.7% |
*Move: change in the closing price from the last close before the report day to the close the day after it. It is filled in a few trading days after each report.
REGN stock reaction to the report
REGN moved +13.33% in the first session that reflects the report (close of Oct 29, 2026 $818.77 to close of Oct 30, 2026 $927.89). Since the report: +17.40% (latest close $961.26 on Nov 2, 2026, against $818.77 before the reaction).
Next REGN earnings report
Regeneron Pharmaceuticals has not announced its next earnings date yet. This page shows a date only once it is confirmed. See the REGN earnings calendar.
ATLAS fair value and signal for REGN
| Last price | $961.26 (+3.6%) |
|---|---|
| ATLAS fair value | $986.58 (range $762.47–$1,276.58) · price is 3% below it |
| Chance of a higher close in 1 month | 49% (normal range $877.79–$1,043.01) |
These are model outputs from the same valuation and calibrated model as the Regeneron Pharmaceuticals stock page. They describe an ordinary period and are not a forecast of any particular outcome.
Regeneron Pharmaceuticals Q3 2026 earnings: frequently asked questions
Did Regeneron Pharmaceuticals beat earnings estimates for Q3 2026?
Regeneron Pharmaceuticals reported EPS of $18.43 against an analyst estimate of $13.76: a beat of $4.67 (33.9%).
When did Regeneron Pharmaceuticals report Q3 2026 results?
Regeneron Pharmaceuticals reported on Friday, October 30, 2026, before the open, for the quarter ended Wednesday, September 30, 2026.
How often does REGN beat EPS estimates?
In its last 4 reports with a recorded result, Regeneron Pharmaceuticals beat the EPS estimate 4 times; the average surprise was +21.7%. Past results do not predict the next one.
How does ATLAS confirm a result?
A result is published only after it is cross-checked: the EODHD earnings calendar and the EODHD fundamentals feed must show the same EPS for the same fiscal period, or the same value must appear in two consecutive checks. Unconfirmed figures are never published. If the figures are revised later, this page updates.
Educational information, not investment advice. Disclaimer